Di Giovanni Giuseppe, Nicholls Stephen J
South Australian Health and Medical Research Institute, Adelaide, Australia.
Victorian Heart Institute, Monash University, Melbourne, Australia.
Am J Prev Cardiol. 2022 Jul 1;11:100366. doi: 10.1016/j.ajpc.2022.100366. eCollection 2022 Sep.
Advances in intravascular imaging have permitted comprehensive evaluation of coronary atherosclerotic plaque from the perspective of its burden and individual components. These advances have been integrated in clinical trials that have evaluated the impact of intensive lipid lowering regimens. These trials have demonstrated that intensive lipid lowering, using high dose statins as monotherapy and in combination with new lipid lowering agents, produce favorable effects on coronary atheroma, resulting in regression and stabilization. These findings provide important biological insights to understand how intensive lipid lowering may reduce cardiovascular risk. This review aims to provide the reader with a contemporary overview of the findings of these studies and to propose the potential clinical implications for management of higher risk patients with atherosclerotic coronary artery disease.
血管内成像技术的进步使得从冠状动脉粥样硬化斑块的负荷及其各个成分的角度进行全面评估成为可能。这些进展已被纳入评估强化降脂方案影响的临床试验中。这些试验表明，使用高剂量他汀类药物单药治疗以及与新型降脂药物联合使用的强化降脂，对冠状动脉粥样瘤产生了有利影响，导致斑块消退和稳定。这些发现为理解强化降脂如何降低心血管风险提供了重要的生物学见解。本综述旨在为读者提供这些研究结果的当代概述，并提出对高危冠状动脉粥样硬化性心脏病患者管理的潜在临床意义。
